kabutan
N225

69,404.50

+0.13%

TOPIX

3,991.14

-0.21%

USDJPY

160.34

-0.01%

Ajinomoto Co., Inc.(2802) Summary

2802
TSE Prime
Ajinomoto Co., Inc.
Result
5,146
JPY
+86
(+1.70%)
Jun 16, 3:30 pm JST
32.11
USD
Jun 16, 2:30 am EDT
PER
40.9
PBR
6.38
Yield
0.97%
Margin Trading Ratio
9.01
PTS
outside of trading hours
Stock Price
Jun 16, 2026
Opening Jun 16, 9:00 am
4,996 JPY 31.17 USD
Previous Close Jun 15
5,060 JPY 31.60 USD
High Jun 16, 3:19 pm
5,175 JPY 32.29 USD
Low Jun 16, 9:00 am
4,979 JPY 31.07 USD
Volume
3,452,600
Trading Value
0.02T JPY 0.11B USD
VWAP
5108.11 JPY 31.88 USD
Minimum Trading Value
514,600 JPY 3,211 USD
Market Capitalization
5.03T JPY 0.03T USD
Number of Trades
8,692
Liquidity & Number of Trades
As of Jun 16, 2026
Liquidity
High
1-Year Average
6,967
1-Year High May 11, 2026
34,456
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jun 5, 2026 123,300 1,111,400 9.01
May 29, 2026 113,300 1,052,100 9.29
May 22, 2026 137,200 1,003,900 7.32
May 15, 2026 173,400 880,900 5.08
May 1, 2026 129,900 867,100 6.68
Company Profile
Ajinomoto Co., Inc. is a leading comprehensive food company, ranking first in seasonings. The company has diversified into pharmaceuticals, animal feed, and other sectors, and is actively pursuing M&A opportunities.
Ajinomoto Co., Inc. is a comprehensive food manufacturer with a primary focus on seasonings, nutritional and processed foods, solution and ingredients, and frozen foods. The company also operates in non-food sectors, including pharmaceutical and food-grade amino acids, biopharmaceutical services (CDMO), and functional materials (such as electronic materials). With numerous subsidiaries both domestically and internationally, Ajinomoto conducts business on a global scale. The company has particularly strong business foundations in Southeast Asia and South America. In the seasoning business, Ajinomoto has local subsidiaries in Thailand, Indonesia, Vietnam, the Philippines, and Malaysia, among others. The frozen food business has also expanded into North America. Additionally, the company is focusing on strengthening its biopharmaceutical services business.